Therapeutics/Diagnostics News

A new ACG guideline published in The American Journal of Gastroenterology underscored that early management “is essential” to prevent complications such as organ failure and pancreatic necrosis in patients with acute pancreatitis.

Topline results from the phase 3 STARS trial showed apraglutide reduced dependency on parenteral support for adult patients with short bowel syndrome with intestinal failure at week 24, Ironwood Pharmaceuticals announced.

Treatment with Stelara for inflammatory bowel disease did not increase the risk for adverse maternal or fetal pregnancy outcomes, and infants exposed in utero reached developmental milestones in the first year of life, data showed.

In this Healio video exclusive, Michael V. Chiorean, MD, explains that physicians can safely and “with confidence” switch patients with inflammatory bowel disease from an originator biologic to a biosimilar at any point during treatment.

Although effective in select patients, the AGA advised against fecal microbiota-based therapies to prevent recurrent Clostridioides difficile infection in severely immunocompromised adults or to treat other gastrointestinal conditions.

In this Healio video exclusive, Miguel Regueiro, MD, shares highlights from his presentation at the GUILD Conference, where he discussed the importance of early, multimodal intervention in perianal fistulizing Crohn’s disease.

LAS VEGAS — A presenter at the Crohn’s & Colitis Congress highlighted tips for successful decision-making with patients with inflammatory bowel disease, including how to approach conversations about the benefits and risks of treatments.

The FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand-conjugated antisense drug for the treatment of familial chylomicronemia syndrome, according to a company release.

The FDA has granted 510(k) clearance to Nanox’s HealthFLD artificial intelligence software to aid clinicians in the detection of fatty liver associated with hepatic steatosis, according to a company press release.

Use of a second anti-tumor necrosis factor agent resulted in early clinical response in nearly 50% of patients with ulcerative colitis and long-term remission in about 30%, with no difference reported between IV and subcutaneous agents.